Anna-maria Lazaratos

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Journal: Cancer treatment reviews

Published: May 01, 2026

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.

Journal: medRxiv : the preprint server for health sciences

Published: August 20, 2025

Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis.

Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: July 26, 2025

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.

Journal: JCO precision oncology

Published: January 27, 2025

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Journal: Current oncology (Toronto, Ont.)

Published: October 15, 2024

A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer.

A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer.

Journal: Translational lung cancer research

Published: September 20, 2024

Antibody-Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases.

Antibody-Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases.

Journal: Current oncology (Toronto, Ont.)

Published: September 19, 2024

CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.

CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.

Journal: The Lancet. Oncology

Published: April 16, 2024

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.

Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.

Journal: Heliyon

Published: September 19, 2023

FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair.

FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair.

Journal: Science advances

Published: August 09, 2023

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

Journal: Breast (Edinburgh, Scotland)

Published: February 03, 2023

GPNMB: a potent inducer of immunosuppression in cancer.

GPNMB: a potent inducer of immunosuppression in cancer.

Journal: Oncogene

Published: May 31, 2022

Showing 1-12 of 12

Last Updated: 09/26/2026